方达控股附属完成收购上海观合医药科技股份有限公司

Core Viewpoint - Fangda Holdings (01521) announced the acquisition of Shanghai Guohe Pharmaceutical Technology Co., Ltd. for 270 million yuan, with all conditions precedent met and the transaction completed on March 3, 2026 [1] Group 1 - The acquisition will result in Shanghai Guohe becoming a wholly-owned subsidiary of Fangda Holdings [1] - The financial performance of the target company and its subsidiaries will be consolidated into the financial statements of the group [1]